Intermittent compression units for severe post-phlebitic syndrome: a randomized crossover study

Ginsberg, Jeffrey S.; Magier, Debbie; Mackinnon, Betsy; Gent, Michael; Hirsh, Jack
May 1999
CMAJ: Canadian Medical Association Journal;5/04/99, Vol. 160 Issue 9, p1303
Academic Journal
Discusses how severe post-phlebitic syndrome may be associated with persistent, intractable pain and swelling that interfere with work and leisure activities. Study to determine if intermittent compression therapy with an extremity pump benefits patients with this condition and, if so, whether the benefit is sustained; Methods; Results; Interpretation.


Related Articles

  • Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis. Agnelli, Giancarlo; Prandoni, Paolo; Santamaria, Maria Gabriella; Bagatella, Paola; Iorio, Alfonso; Bazzan, Mario; Moia, Marco; Guazzaloca, Giuliana; Bertoldi, Adriano; Tomasi, Cristina; Scannapieco, Gianluigi; Ascani, Alessandra; Villalta, Sabina; Frulla, Michela; Mosena, Laura; Girolami, Antonio; Vaccarino, Antonella; Alatri, Adriano; Palareti, Gualtiero; Marchesi, Mario // New England Journal of Medicine;7/19/2001, Vol. 345 Issue 3, p165 

    Background: In patients with idiopathic deep venous thrombosis, continuing anticoagulant therapy beyond three months is associated with a reduced incidence of recurrent thrombosis during the period of therapy. Whether this benefit persists after anticoagulant therapy is discontinued is...

  • Outpatient Management of Lower Extremity DVT. Kirchner, Jeffrey T. // American Family Physician;11/1/1999, Vol. 60 Issue 7, p2137 

    Provides information on the treatment for deep venous thrombosis (DVT). Effectiveness of the administration of low-molecular-weight heparin; Application of exclusion criteria to patients with proximal DVT.

  • Body platelet testing to guide antiplatelet therapy: Implications of the GRAVITAS trial. Faxon, David P. // Hem/Onc Today;3/10/2011, Vol. 12 Issue 5, p34 

    The author comments on the implications of the Gauging Responsiveness with A VerifyNow assay--Impact on Thrombosis and Safety (GRAVITAS) trial for the testing of platelet-guided therapy.

  • Venous Thrombosis Treated with Continuous IV Heparin. Apgar, Barbara // American Family Physician;11/1/1996, Vol. 54 Issue 6, p2106 

    Presents a summary of the article `The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin,' by S. Anand from `Archives of Internal Medicine' dated 1996. Methods used in the study;...

  • Žilní trombózy u dÄ›tských pacientů s akutní lymfoblastickou leukemií. Cingrošová, L.; Zdráhalová, K.; Šrámková, L.; Suková, M.; Hadačová, I.; Procházková, D.; Starý, J. // Transfusiology & Haematology Today / Transfuze a Hematologie Dne;Mar2012, Vol. 18 Issue 1, p19 

    In 2005-2010, six patients (3.9%) out of total 154 children treated for acute lymphoblastic leukaemia developed symptomatic venous thrombosis. Venous thrombosis occurred in 4 cases during induction, once during re-induction and once after the 4th block of chemotherapy for ALL relapse. Out of the...

  • OTHER NEWS TO NOTE.  // BioWorld International;12/10/2008, Vol. 13 Issue 50, p3 

    This section offers biotechnology industry news briefs. Ghent, Belgium-based Ablynx NV has initiated a double-blind, randomized, placebo-controlled Phase I study of its antithrombotic Nanobody ALX-0681 in healthy volunteers. The Finnish National Agency for Medicines has renewed the license of...

  • Agents to Control Bleeding Show Promise. Hampton, Tracy // JAMA: Journal of the American Medical Association;1/24/2007, Vol. 297 Issue 4, p349 

    The article describes clinical trials that examined the use of anticoagulants to prevent bleeding in patients at risk of venous thrombolism who are treated with anticoagulants and in patients with thrombocytopenia. A trial funded by Sanofi-Aventis studied the use of the anticoagulant idraparinux...

  • Benefit-Risk Assessment of Treatments for Heparin-Induced Thrombocytopenia. Messmore, Harry L.; Jeske, Walter P.; Wehrmacher, William H.; Walenga, Jeanine M. // Drug Safety;Jul2003, Vol. 26 Issue 9, p625 

    Patients with heparin-induced thrombocytopenia (HIT) are at high risk of thrombosis and should be treated with alternative anticoagulant therapy to reduce complications. The current treatment of choice is one of the approved direct thrombin inhibitors, argatroban or lepirudin. These drugs have...

  • Neutralization of Prostaglandin E1, Intravenous Solution Reduces Infusion Phlebitis. Fujita, Masanori // Angiology;Sep2000, Vol. 51 Issue 9, p719 

    Investigates how to continue prostaglandin E1 infusion therapy for three weeks with tolerable phlebitis. Use of reduced amount of fluid to prevent volume overload; Frequency and severity of phlebitis among patients receiving prostaglandin infusion twice daily; Determination of the severity of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics